Autism and developmental disability caused by KCNQ3 gain-of-function variants.


Journal

Annals of neurology
ISSN: 1531-8249
Titre abrégé: Ann Neurol
Pays: United States
ID NLM: 7707449

Informations de publication

Date de publication:
08 2019
Historique:
received: 20 01 2019
revised: 03 06 2019
accepted: 06 06 2019
pubmed: 10 6 2019
medline: 31 3 2020
entrez: 10 6 2019
Statut: ppublish

Résumé

Recent reports have described single individuals with neurodevelopmental disability (NDD) harboring heterozygous KCNQ3 de novo variants (DNVs). We sought to assess whether pathogenic variants in KCNQ3 cause NDD and to elucidate the associated phenotype and molecular mechanisms. Patients with NDD and KCNQ3 DNVs were identified through an international collaboration. Phenotypes were characterized by clinical assessment, review of charts, electroencephalographic (EEG) recordings, and parental interview. Functional consequences of variants were analyzed in vitro by patch-clamp recording. Eleven patients were assessed. They had recurrent heterozygous DNVs in KCNQ3 affecting residues R230 (R230C, R230H, R230S) and R227 (R227Q). All patients exhibited global developmental delay within the first 2 years of life. Most (8/11, 73%) were nonverbal or had a few words only. All patients had autistic features, and autism spectrum disorder (ASD) was diagnosed in 5 of 11 (45%). EEGs performed before 10 years of age revealed frequent sleep-activated multifocal epileptiform discharges in 8 of 11 (73%). For 6 of 9 (67%) recorded between 1.5 and 6 years of age, spikes became near-continuous during sleep. Interestingly, most patients (9/11, 82%) did not have seizures, and no patient had seizures in the neonatal period. Voltage-clamp recordings of the mutant KCNQ3 channels revealed gain-of-function (GoF) effects. Specific GoF variants in KCNQ3 cause NDD, ASD, and abundant sleep-activated spikes. This new phenotype contrasts both with self-limited neonatal epilepsy due to KCNQ3 partial loss of function, and with the neonatal or infantile onset epileptic encephalopathies due to KCNQ2 GoF. ANN NEUROL 2019;86:181-192.

Identifiants

pubmed: 31177578
doi: 10.1002/ana.25522
doi:

Substances chimiques

KCNQ3 Potassium Channel 0
KCNQ3 protein, human 0

Types de publication

Case Reports Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

181-192

Subventions

Organisme : University of Naples "Federico II" and Compagnia di San Paolo within the STAR Program "Sostegno Territoriale alle Attività di Ricerca"
ID : 6-CSP-UNINA-120
Pays : International
Organisme : NINDS NIH HHS
ID : R01 NS069605
Pays : United States
Organisme : University Research Fund-University of Antwerp
ID : FFB180053
Pays : International
Organisme : NINDS NIH HHS
ID : R01 NS049119
Pays : United States
Organisme : Telethon Foundation
ID : GGP15113
Pays : International
Organisme : Duke Genome Sequencing Clinic
Pays : International
Organisme : Italian Ministry for University and Research
ID : PRIN2017YH3SXK
Pays : International
Organisme : Miles Family Fund
Pays : International
Organisme : KCNQ2 Cure Alliance
Pays : International
Organisme : NINDS NIH HHS
ID : R01 NS49119
Pays : United States
Organisme : Scientific Research Flanders
ID : 1861419N
Pays : International
Organisme : Italian Ministry of Health Ricerca Finalizzata Giovani Ricercatori 2016
ID : GR-2016-02363337
Pays : International
Organisme : National Genomics Infrastructure Sweden and Science
Pays : International
Organisme : Duke University Health System
Pays : International
Organisme : Italian Ministry for University and Research
ID : RBSI1444EM
Pays : International

Informations de copyright

© 2019 American Neurological Association.

Auteurs

Tristan T Sands (TT)

Department of Neurology, Columbia University Medical Center, New York, NY.
Institute for Genomic Medicine, Columbia University Medical Center, New York, NY.

Francesco Miceli (F)

Section of Pharmacology, Department of Neuroscience, University of Naples "Federico II,", Naples, Italy.

Gaetan Lesca (G)

Department of Medical Genetics, Reference Center for Developmental Anomalies, Civil Hospices of Lyon, Lyon, France.
French Institute of Health and Medical Research U1028, French National Center for Scientific Research UMR5292, Center for Research in Neuroscience in Lyon, Genetics of Neurodevelopment Team, Claude Bernard University Lyon 1, Lyon, France.
Claude Bernard University Lyon 1, Lyon, France.

Anita E Beck (AE)

Division of Genetic Medicine, Department of Pediatrics, University of Washington, Seattle, WA.
Seattle Children's Hospital, Seattle, WA.

Lynette G Sadleir (LG)

Department of Paediatrics and Child Health, University of Otago, Wellington, New Zealand.

Daniel K Arrington (DK)

Children's Neurology, St Luke's Children's Hospital, Boise, ID.

Bitten Schönewolf-Greulich (B)

Center for Rett Syndrome, Department of Pediatrics and Adolescent Medicine, National Hospital, Copenhagen, Denmark.
Kennedy Center, Department of Clinical Genetics, Copenhagen University Hospital, Rigshospitalet and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Sébastien Moutton (S)

French Institute of Health and Medical Research U1231, Laboratory of Cognitive Neuroscience UMR1231, Genetics of Developmental Anomalies, Burgundy University, F-21000, Dijon, France.

Anna Lauritano (A)

Section of Pharmacology, Department of Neuroscience, University of Naples "Federico II,", Naples, Italy.

Piera Nappi (P)

Section of Pharmacology, Department of Neuroscience, University of Naples "Federico II,", Naples, Italy.

Maria Virginia Soldovieri (MV)

Department of Medicine and Health Sciences "Vincenzo Tiberio", University of Molise, Campobasso, Italy.

Ingrid E Scheffer (IE)

University of Melbourne, Austin Health, Royal Children's Hospital, Florey and Murdoch Institutes, Melbourne, Victoria, Australia.

Heather C Mefford (HC)

Division of Genetic Medicine, Department of Pediatrics, University of Washington, Seattle, WA.

Nicholas Stong (N)

Institute for Genomic Medicine, Columbia University Medical Center, New York, NY.

Erin L Heinzen (EL)

Institute for Genomic Medicine, Columbia University Medical Center, New York, NY.

David B Goldstein (DB)

Institute for Genomic Medicine, Columbia University Medical Center, New York, NY.

Ana Grijalvo Perez (AG)

Department of Neurology, University of California, San Francisco, San Francisco, CA.

Eric H Kossoff (EH)

Departments of Pediatrics and Neurology, Johns Hopkins School of Medicine, Baltimore, MD.

Amber Stocco (A)

Pediatric Neurology, INTEGRIS Baptist Medical Center, Oklahoma City, OK.

Jennifer A Sullivan (JA)

Division of Medical Genetics, Department of Pediatrics, Duke University, Durham, NC.

Vandana Shashi (V)

Division of Medical Genetics, Department of Pediatrics, Duke University, Durham, NC.

Benedicte Gerard (B)

Molecular Genetic Unit, Strasbourg University Hospital, Strasbourg, France.

Christine Francannet (C)

Genetics Department, Reference Center for Developmental Anomalies, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.

Anne-Marie Bisgaard (AM)

Center for Rett Syndrome, Department of Pediatrics and Adolescent Medicine, National Hospital, Copenhagen, Denmark.

Zeynep Tümer (Z)

Kennedy Center, Department of Clinical Genetics, Copenhagen University Hospital, Rigshospitalet and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Marjolaine Willems (M)

Reference Center for Developmental Disorders, Department of Medical Genetics, Arnaud de Villeneuve Hospital, Montpellier University Hospital, Montpellier, France.

François Rivier (F)

Department of Pediatric Neurology, University Hospital of Montpellier, and Physiology and Experimental Medicine of Heart and Muscle Unit, University of Montpellier, National Institute for Health and Medical Research, French National Center for Scientific Research, Montpellier, France.

Antonio Vitobello (A)

Functional Unit 12, Innovation in Genomic Diagnosis of Rare Diseases, University Hospital Dijon-Bourgogne, Dijon, France.

Kavita Thakkar (K)

Division of Neurology, Department of Pediatrics, Children's Hospital of Pittsburgh and University of Pittsburgh School of Medicine, Pittsburgh, PA.

Deepa S Rajan (DS)

Division of Neurology, Department of Pediatrics, Children's Hospital of Pittsburgh and University of Pittsburgh School of Medicine, Pittsburgh, PA.

A James Barkovich (AJ)

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA.

Sarah Weckhuysen (S)

Neurogenetics Group, University of Antwerp, Antwerp, Belgium.
Neurology Department, University Hospital Antwerp, Antwerp, Belgium.

Edward C Cooper (EC)

Departments of Neurology, Neuroscience, and Molecular and Human Genetics, Baylor College of Medicine, Houston, TX.

Maurizio Taglialatela (M)

Section of Pharmacology, Department of Neuroscience, University of Naples "Federico II,", Naples, Italy.

M Roberta Cilio (MR)

Department of Neurology, University of California, San Francisco, San Francisco, CA.
Departments of Pediatrics and Institute of Experimental and Clinical Research, University of Louvain, Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH